Latest From Scorpius

Scorpius' Ania Szymanska Featured in Pharmaceutical Technology’s February 2024 E-book

Scorpius BioManufacturing's Site Head of Quality, Ania Szymanska shares her expertise on how to evaluate a CDMO’s commitment to quality in Pharmaceutical Technology’s February 2024 E-book.

From frustration to innovation: a CDMO’s mission to empower emerging biotechs

Capacity, capacity, capacity. This seems to be all the industry talks about. A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.

October 20, 2023

Does Your Biologics CDMO Truly Have a Culture of Quality?

Joe Payne, Scorpius' President & COO, shares what 20+ years in pharma has taught him about creating a culture of quality.

Biologics Outsourcing: Decision Drivers and Key Considerations

A recent survey of 100 decision makers at innovative biologics companies revealed 57% of respondents believe their companies’ outsourcing activities will increase over the next two years, while a furt...

An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market

By providing end-to-end services — including secure supply chains — CRO/CDMOs, like Scorpius BioManufacturing can help biologics developers meet accelerated timelines and establish a real competitive ...

January 31, 2023

The Bioanalytical Development Journey

Biopharma companies outsource pharmaceutical development and manufacturing from discovery, bioanalytical testing, qualification to validation.

Evaluating Single-Use Technologies for Biomanufacturing

Single-use technologies (SUTs) are ideal for multiproduct facilities producing smaller volumes of materials.

November 22, 2021

ABC: Analytics for Biomanufacturing and Clinical Trials of Biomanufactured Products

Samir Lakhashe, Director, Bioanalysis, discusses assay categorization, the company's growing toolbox, predictions for the future, and what scientists who want to join the growing team should know, wit...

October 15, 2021